Published in:
Open Access
01-12-2010 | Poster presentation
Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
Authors:
S Spinosa-Guzman, T Van de Casteele, G De La Rosa, P De Doncker
Published in:
Journal of the International AIDS Society
|
Special Issue 4/2010
Login to get access
Excerpt
The open-label, Phase III, ODIN trial randomised treatment-experienced HIV-1-infected patients with no DRV resistance-associated mutations (RAMs) to receive DRV/r 800/100mg qd or DRV/r 600/100mg bid, plus an optimised background regimen (≥2 NRTIs). Non-inferiority in the primary endpoint of virological response at Week 48 was demonstrated with DRV/r qd versus bid dosing: 72.1% vs 70.9% of patients, respectively, achieved HIV-1 RNA <50 copies/mL (95% CI: -6.1, 8.5; p<0.001; ITT-TLOVR). The current analysis explores patient-reported HRQoL. …